DexCom news
The WiseView Research desk's stories that name DexCom, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The DXCM page →
- HeadlineDexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
- HeadlineDid DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- HeadlineDexCom Gears Up to Report Q3 Results: How to Play the Stock?
- Market closeS&P 500, Dow and Nasdaq Close Higher as Tech Leads Wednesday Rally
The S&P 500 rose 0.59%, the Dow 0.69% and the Nasdaq led with a 1.05% gain Wednesday, as technology stocks paced the advance.
- HeadlineDexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
- HeadlineDexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives
- HeadlineHealth Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
- HeadlineLandmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- HeadlineHere's Why You Should Retain DexCom Stock in Your Portfolio for Now
- HeadlineDexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- HeadlineDXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
- HeadlineHere's Why DexCom (DXCM) is a Strong Growth Stock
- CongressRo Khanna bought $1,001 - $15,000 of DXCM
- CongressRo Khanna bought $1,001 - $15,000 of DXCM
- CongressJohn Boozman bought $1,001 - $15,000 of DXCM
- CongressMichael McCaul bought $1,001 - $15,000 of DXCM
- CongressRo Khanna sold $1,001 - $15,000 of DXCM
- CongressMichael McCaul bought $15,001 - $50,000 of DXCM
- CongressMichael McCaul sold $15,001 - $50,000 of DXCM
- CongressRob Bresnahan bought $1,001 - $15,000 of DXCM
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.